We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02739165
Recruitment Status : Completed
First Posted : April 15, 2016
Last Update Posted : January 18, 2019
Information provided by (Responsible Party):
Asahi Kasei Pharma Corporation

Brief Summary:
The purpose of this study is to assess the efficacy and safety of the intravenous drip infusion of ART-123 in patients with acute exacerbation of idiopathic pulmonary fibrosis (IPF) in a multicenter, double-blind, randomized, placebo-controlled, parallel group comparison study, and to confirm its superiority over placebo with survival rate on Day 90 as the primary endpoint.

Condition or disease Intervention/treatment Phase
Idiopathic Pulmonary Fibrosis Drug: ART-123 Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 74 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase III Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Multicenter Randomized Placebo-controlled Double-blind Study to Assess the Efficacy and Safety of ART-123
Study Start Date : May 2016
Actual Primary Completion Date : September 2018
Actual Study Completion Date : December 2018

Arm Intervention/treatment
Experimental: ART-123 Drug: ART-123
380 U/kg/day by intravenous drip infusion in addition to standard of care steroid therapy

Placebo Comparator: Placebo Drug: Placebo
Placebo by intravenous drip infusion in addition to standard of care steroid therapy

Primary Outcome Measures :
  1. Survival rate on Day 90 [ Time Frame: 90 days ]

Secondary Outcome Measures :
  1. Overall survival [ Time Frame: 180 days after the start of investigational product administration in the last subject ]
  2. Survival time up to Day 90 [ Time Frame: 90days ]
  3. P/F ratio [ Time Frame: 4 days, 7 days, 15 days, 28 days, 60 days, 90 days ]
  4. Coagulation tests [ Time Frame: 4 days, 7 days, 15days, 28 days, 60 days, 90 days ]

Other Outcome Measures:
  1. Chest imaging findings (chest HRCT findings) [ Time Frame: Within 90days ]
  2. Blood gas test [ Time Frame: Within 90days ]
  3. mMRC [ Time Frame: Within 90days ]
  4. CAT [ Time Frame: Within 90days ]
  5. Dyspnea-12 [ Time Frame: Within 90days ]
  6. Duration of respiration management [ Time Frame: Within 90days ]
  7. Inflammatory markers [ Time Frame: Within 90days ]
  8. Interstitial pneumonia markers [ Time Frame: Within 90days ]
  9. Total duration of respiratory system-related inpatient hospitalization [ Time Frame: Within 90days ]
  10. Adverse events (AEs) [ Time Frame: Within 90days ]
  11. AEs related to hemorrhage [ Time Frame: Within 90days ]
  12. Routine laboratory tests [ Time Frame: Within 90days ]
  13. Vital signs [ Time Frame: Within 90days ]
  14. Presence of anti-drug antibodies [ Time Frame: Within 90days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Main Inclusion Criteria:

  • Patients diagnosed with IPF who meet all criteria from (1) through (4) during the course of IPF
  • (1)Unexplained development or worsening of dyspnea within 1 month during the course of IPF
  • (2)Finding of new, bilateral ground glass opacities and/or consolidation on HRCT
  • (3)No apparent Pulmonary infections, pneumothorax, malignant tumors, pulmonary embolism, or left heart failure
  • (4)A decrease* in PaO2 of ≥10 mmHg or SpO2 of ≥4% under the same conditions compared with the level at the previous measurements

    • (*) In cases where no PaO2 or SpO2 test values under the same conditions are available, a patient with a P/F ratio ≤300 in the current episode of acute exacerbation is considered to have met criterion (4)
  • Aged 40 years or older and no older than 85 years at the time of informed consent with either sex

Main Exclusion Criteria:

  • Have intracranial hemorrhage, pulmonary hemorrhage, gastrointestinal bleeding (continued hematemesis, bloody discharge, gastrointestinal ulcer-induced hemorrhage)
  • Have a history of cerebrovascular disorder (e.g., cerebral hemorrhage or cerebral infarction) within 52 weeks (364 days) before informed consent
  • Patients for whom the completion of hemostatic treatment has not been confirmed after undergoing surgery of the central nervous system or after trauma
  • Have a high risk for fatal or life-threatening hemorrhage
  • Patients with malignant tumors
  • Have acute exacerbation attributable to drug induced pulmonary disorder, after surgery for malignant tumors, chemotherapy, or radiation therapy
  • Have acute exacerbation due to a thoracic surgical procedure (including thoracoscopic lung biopsy)
  • Have a history of acute exacerbation of IPF
  • Receiving mechanical ventilation through intratracheal intubation
  • Patients who are pregnant or nursing, or who may be pregnant
  • Patients with a platelet count less than 100,000/uL at the time of enrollment
  • Patients with severe renal (serum Cr: ≥4 mg/dL) or hepatic (AST/ALT: ≥500 IU/L or T-Bil: ≥10 mg/dL) dysfunction
  • Have been administered a commercially available thrombomodulin alfa (recombinant )(Recomodulin® for Intravenous Injection 12800) within 30 days before the start of investigational product administration
  • Have a history of hypersensitivity for investigational product

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02739165

Layout table for location information
Nagoya, Aichi, Japan
Seto, Aichi, Japan
Kamogawa, Chiba, Japan
Sakura, Chiba, Japan
Kurume, Fukuoka, Japan
Ogaki, Gifu, Japan
Himeji, Hyogo, Japan
Kobe, Hyogo, Japan
Naka, Ibaragi, Japan
Yokohama, Kanagawa, Japan
Sendai, Miyagi, Japan
Tenri, Nara, Japan
Kurashiki, Okanaya, Japan
Osakasayama, Osaka, Japan
Sakai, Osaka, Japan
Hamamatsu, Shizuoka, Japan
Shimotsuke, Tochigi, Japan
Bunkyo, Tokyo, Japan
Minato, Tokyo, Japan
Ota, Tokyo, Japan
Shibuya, Tokyo, Japan
Shinjuku, Tokyo, Japan
Chiba, Japan
Fukuoka, Japan
Kumamoto, Japan
Nagasaki, Japan
Sponsors and Collaborators
Asahi Kasei Pharma Corporation
Layout table for investigator information
Study Chair: Asahi Kasei Pharma Corporation Asahi Kasei Pharma Corporation
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Asahi Kasei Pharma Corporation
ClinicalTrials.gov Identifier: NCT02739165    
Other Study ID Numbers: ART-123-AEIPF-301
First Posted: April 15, 2016    Key Record Dates
Last Update Posted: January 18, 2019
Last Verified: July 2017
Keywords provided by Asahi Kasei Pharma Corporation:
Acute exacerbations
Idiopathic pulmonary fibrosis
Recombinant human soluble thrombomodulin
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases